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Abstract
Background: This study investigates the implementation of a new intensity modulated arc therapy (IMAT) class solution
in comparison to a 6-static beam step-and-shoot intensity modulated radiotherapy (s-IMRT) for three-phase adaptive
18F-FDG-PET-voxel-based dose-painting-by-numbers (DPBN) for head-and-neck cancer.
Methods: We developed 18F-FDG-PET-voxel intensity-based IMAT employing multiple arcs and compared it to clinically
used s-IMRT DPBN. Three IMAT plans using 18F-FDG-PET/CT acquired before treatment (phase I), after 8 fractions (phase II)
and CT acquired after 18 fractions (phase III) were generated for each of 10 patients treated with 3 s-IMRT plans based on
the same image sets. Based on deformable image registration (ABAS, version 0.41, Elekta CMS Software, Maryland Heights,
MO), doses of the 3 plans were summed on the pretreatment CT using validated in-house developed software.
Dosimetric indices in targets and organs-at-risk (OARs), biologic conformity of treatment plans set at ≤5 %, treatment
quality and efficiency were compared between IMAT and s-IMRT for the whole group and for individual patients.
Results: Doses to most organs-at-risk (OARs) were significantly better in IMAT plans, while target levels were similar for
both types of plans. On average, IMAT ipsilateral and contralateral parotid mean doses were 14.0 % (p = 0.001) and 12.7 %
(p < 0.001) lower, respectively. Pharyngeal constrictors D50% levels were similar or reduced with up to 54.9 % for IMAT
compared to s-IMRT for individual patient cases. IMAT significantly improved biologic conformity by 2.1 % for treatment
phases I and II. 3D phantom measurements reported an agreement of ≥95 % for 3 % and 3 mm criteria for both
treatment modalities. IMAT delivery time was significantly shortened on average by 41.1 %.
Conclusions: IMAT implementation significantly improved the biologic conformity as compared to s-IMRT in adaptive
dose-escalated DPBN treatments. The better OAR sparing and faster delivery highly improved the treatment efficiency.
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and-neck cancer
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Background
Intensity-modulated radiation therapy (IMRT) has become
a standard treatment of head-and-neck cancer due to its
ability to decrease radiation-induced toxicity [1–3], though
the survival rates have not been significantly improved.
Since its introduction, different delivery techniques have
evolved to make IMRT faster, more precise and flexible. At
present, static, dynamic and rotational IMRT are in use
demonstrating comparable dose coverage and conformity
[4, 5]. Because of a faster delivery, rotational techniques
like intensity-modulated arc therapy (IMAT) gained wide-
spread use over recent years. A comparison of different ro-
tational techniques has already been done in literature and
it is beyond the scope of this paper [6]. Commercial solu-
tions to perform IMAT are currently available for as well
Elekta (Crawley, UK) as Varian (Palo Alto, CA, USA).
In planning studies for head-and-neck cancer, IMAT
demonstrated better sparing of organs-at-risk (OARs) with-
out increasing integral dose when compared to static or
dynamic IMRT [4–6]. IMAT has the ability to modulate
intensities at an infinite number of gantry angles resulting
in superior, highly structured dose distributions that are
needed for dose painting, i.e., mapping dose to tumor het-
erogeneity detected by biologic imaging. Up to now, clinical
dose-painting by numbers for head-and-neck cancer was
based on non-rotational IMRT [7, 8]. The potential of bio-
logical image-based IMAT has not been explored yet. We
developed an 18F-FDG-PET-voxel intensity-based IMAT
class solution and investigated its possible implementation
in comparison to clinically used adaptive step-and-shoot
18F-FDG-PET-voxel intensity-based IMRT (s-IMRT). Here-
with we present the results of our study.
Methods
Study population
The first 10 head-and-neck cancer patients treated with
adaptive 18F-FDG-PET-voxel intensity-based IMRT in
a randomized phase II dose-escalation clinical trial
(NCT01341535) were selected for this study (Table 1).
All tumors were biopsy-proven non-metastatic head-
and-neck squamous cell carcinomas.
Imaging and target definition
All patients were positioned with a five-point thermoplas-
tic mask (Orfit Industries N.V., Belgium), which extended
down to the shoulders, during computed-tomography
(CT) isocenter simulation and treatment delivery. Planning
CT scans of 3 mm slice thickness were acquired before the
treatment and after the 8th and 18th fraction. A verification
CT was taken at the treatment end. Contrast-enhanced
18F-FDG-PET/CT (Philips Medical Systems, Germany)
was performed before treatment and after the 8th frac-
tion. 18F-FDG-PET-images were acquired with a voxel
size of 4 x 4 x 4 mm3 as described earlier [9]. Fusion of
the planning CT and 18F-FDG-PET/CT scans was done
on a Pinnacle treatment planning system, version 9.0
(Philips Medical Systems, Andover, MA).
Delineation of the gross tumor volume of the primary
tumor (GTVT) and pathological lymph nodes (GTVN)
was done using mutual information of both anatomical
and biological imaging. A threshold level of 50 % of
SUVMAX (maximal standardised uptake value) was set
for 18F-FDG-uptake in Pinnacle. Pathologic lymph nodes
were delineated separately and noted as the GTVN1 and
GTVN2. The high-risk clinical target volume (CTVHR) was
created combining the GTVN and a three-dimensional
expansion of the GTVT with 1 cm and adjusted to the air
cavities and uninvolved bones. 3 mm margin to the CTVHR
was used to create the high risk planning target volume
(PTVHR). Delineation of the elective neck regions according
to the guidelines of Gregoire et al. [10] resulted in the CTV
of the elective neck (CTVEN) and the elective neck PTV
(PTVEN) after a 3 mm expansion in all directions.
The considered organs-at-risk (OARs) were spinal cord,
brainstem, swallowing structures defined as one region-
of-interest (superior, medial and inferior pharyngeal con-
strictor, upper oesophageal sphincter, first 2 cm of the
oesophagus and supraglottic larynx), parotids and man-
dible. Planning OAR volumes (PRVs) were created for the
spinal cord and brainstem by three-dimensional expan-
sions of 5 mm and 3 mm, respectively.
Deformable image co-registration (ABAS, version 0.41,
Elekta CMS Software, Maryland Heights, MO) was used
to propagate the targets and OAR contours from one CT
to another in chronological order. All structures were
reviewed and edited if necessary by an experienced head-
and-neck radiation oncologist.
Dose prescription and treatment planning
Treatment phases I, II and III consisted of 10 fractions
planned on the 1st, 2nd and 3rd CT set, respectively.
Dose-painting was performed in GTVT and GTVN dur-
ing the first 20 fractions. The dose range was between
Table 1 Patient characteristics
Patient No. Age (years) Tumor site Tumor subsite TN-stage
1 64 Oropharynx Tonsil cT4a pN2b
2 48 Oropharynx Base of Tongue cT1 cN2c
3 54 Oropharynx Tonsil cT4a cN2c
4 74 Hypopharynx Aryepiglottic Fold cT2 cN1
5 40 Hypopharynx Piriform Sinus cT1 pN2a
6 53 Larynx Glottis cT3 cN0
7 52 Oropharynx Vallecula cT1 pN2b
8 54 Oropharynx Tonsil cT2 cN2c
9 59 Larynx Supraglottis cT2 cN0
10 58 Oropharynx Vallecula cT4a cN2c
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2.2 Gy and 3.1 Gy per fraction in phases I and II. Only a
GTVT volume ≤ 1.75 cm
3 was allowed to receive more
than 2.9 Gy per fraction. GTVN was dose-painted in 4
out of 6 patients with N+ disease; in the 2 other patients,
which had a pathological lymph node volume ≤ 4 cm3,
the GTVN median prescription dose was 2.2 Gy per frac-
tion. The total dose range for the GTVT and GTVN was
66-83 Gy.
No dose-painting was performed during the last 10
fractions, where a D95% of 2.0 Gy/fx was prescribed to
PTVHR. Elective neck was irradiated during fractions 1-
20 with a median total dose prescription of 40 Gy to
PTVEN. GTVT and GTVN biologic conformity was mea-
sured by a quality factor (QF), defined as the mean devi-
ation between prescribed and planned dose in each
PET/CT voxel [9]. QF was kept below 5 % where pos-
sible. Every treatment was planned to a total of 30 frac-
tions and then rescaled to 10 fractions. Maximum doses
of 50, 60 and 70 Gy were allowed to < 5 % of the spinal
cord (PRV), brainstem (PRV) and mandible, respectively.
A maximal dose of less than 45 Gy for the spinal cord,
50 Gy for the brainstem and 27 Gy to < 50 % of the vol-
ume of the spared parotids, respectively, were consid-
ered clinically acceptable.
The methodology of 18F-FDG-PET voxel intensity-
based DPBN has been previously discussed [9]. Briefly, a
dose is prescribed to the voxels in the dose-painted tar-
get volume as a function of signal intensity as follows:
D Ið Þ ¼ Dlow I ≤Ilow
D Ið Þ ¼ Dlowþ I−IlowIhigh−Ilow Dhigh−Dlow
 
Ilow≤I≤Ihigh
D Ið Þ ¼ Dhigh Ihigh≤I
where the signal intensities Ihigh and Ilow are determined
as 95 % of the maximum 18F-FDG-PET intensity and as
25 % of Ihigh, respectively. The extension of the discrete
PET intensity data to the continuum was implemented
using trilinear interpolation for the randomly seeded
points in the delineated volumes. Using the PET-
intensity to dose relation, the dose prescription was on a
point-by-point base.
All treatment plans were created for an Elekta linac
(Crawley, UK) equipped with a standard multileaf colli-
mator with 40 leaf pairs, capable of delivering s-IMRT
and IMAT with variable dose rate, gantry and collimator
rotation speed. In-house developed software using an
anatomy- and 18F-FDG-PET-voxel intensity-based seg-
mentation tool (ABST, BBST) followed by leaf position
and monitor unit (MU) optimization was used for treat-
ment planning [11, 12].
s-IMRT plans consisted of six non-opposing coplanar
6 MV beams with gantry angles of 45°, 75°, 165°, 195°,
285° and 315°. The IMAT class solution was made of 6
MV arcs collimated around PTVEN (gantry angle from
-176° to 176°) and PTVHR (144° to -144°) with control
points (CPs) defined every 8°. The only constraints were
on the physical abilities of the linear accelerator to de-
liver the treatment (maximum gantry speed, maximum
collimator rotation speed, maximum leaf speed, mini-
mum dose rate), and a minimum distance constraint of
1 cm for opposite and diagonally-opposite leaves of the
MLC. ABST [11] was used to create the starting set of
CPs, resulting in multiple initial arcs, avoiding both pa-
rotids, the swallowing structures and the PRV of the
spinal cord. The CPs were optimized as described previ-
ously [12]. ABST generates beam segments with leaf and
jaw positions based on a beams-eye-view projection of
selected PTVs and OARs. BBST additionally takes into
account PET-intensities to create initial beam segments
shapes [9]. For a faster delivery, the parts of the arcs
with a contribution of less than 2 MUs were eliminated
during the optimization leading to the split of the arcs in
sub-arcs. A CP refinement was performed by interpolating
and generating additional CPs within the arcs, followed by
MU and leaf position optimization. This CP refinement
limited MU differences, gantry and collimator angle differ-
ences, leaf and jaw position movements between CPs and
was applied to reach the accuracy constraints used in the
treatment verification. After the final optimization, the
remaining arcs were linked together in one beam accord-
ing to the shortest possible delivery time. All dose compu-
tations were done in Pinnacle with a collapsed cone
convolution/superposition calculation algorithm.
Dose reporting and statistical analysis
Doses of the 3 treatment plans were summed on the pre-
treatment CT using in-house developed software [13]
based on the deformable CT image registrations made
with the ABAS software. The reporting of the region-of-
interest (ROI) dose levels was done on the summed doses.
To assess the risk of inducing secondary malignancies,
the integral dose was calculated in the patient volume as
follows:
ID ¼ Dmean⋅V⋅ρ
where Dmean is the mean dose, V is the volume and ρ
the tissue density, which was considered to be 1 g/cm3.
Statistical tests of dosimetric, biologic conformity, treat-
ment verification and quality (MUs and delivery time) dif-
ferences between s-IMRT and IMAT were done using a
two-sided Wilcoxon matched-pair signed rank test with
SPSS software version 20.0 (SPSS Inc., Chicago, IL).
Differences were considered statistically significant for
p-values <0.05.
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Table 2 Population average dose levels for s-IMRT and IMAT treatments
Target/Organ-at-risk s-IMRT (Gy) IMAT (Gy) p-value
GTVT
D2% 80.4 (76.4 - 83.7) 81.0 (77.2 - 85.1) 0.175
D98% 67.3 (63.8 – 71.0) 68.4 (64.8 - 73.6) 0.009
GTVN
D2% 73.3 (66.4 - 79.3) 74.8 (67.2 - 81.0) 0.014*
D98% 64.8 (62.5 - 69.9) 66.3 (63.1 - 72.8) 0.043*
PTVHR
D2% 76.9 (74.5 - 79.6) 77.9 (75.8 - 79.3) 0.013
D98% 57.5 (54.3 - 59.4) 56.9 (52.5 - 58.7) 0.160
PTVEN
D2% 66.0 (61.1 - 73.3) 67.0 (62.0 – 76.0) 0.005
D98% 32.2 (21.2 - 42.2) 32.7 (20.2 - 40.8) 0.452
CTVHR
D2% 78.1 (75.6 - 81.2) 79.1 (76.6 - 81.3) 0.023
D98% 60.9 (59.6 - 61.6) 60.3 (58.9 - 61.5) 0.025
CTVEN
D2% 66.5 (59.7 - 75.9) 67.8 (61.7 - 77.9) 0.001
D98% 38.9 (35.2 - 44.5) 38.6 (34.1 - 42.2) 0.222
Spinal cord PRV
D5% 32.4 (29.5 - 34.7) 28.4 (23 - 35.3) 0.003
D50% 21.4 (3.5 - 28.5) 13.6 (1.8 - 21.5) 0.001
Brainstem PRV
D5% 20.5 (12.4 - 28.4) 14.2 (6.1 - 23.6) <0.001
D50% 2.3 (1.4 - 3.1) 2.1 (1.1 - 3.4) 0.019
Ipsilateral parotid
V27Gy 43.8 (34.8 - 52.5) 36.6 (24.6 - 48.1) 0.007
Dmean 25.8 (18.7 - 31.8) 22.2 (14.9 - 29.4) 0.001
Contralateral parotid
V27Gy 40.0 (27.6 - 50.1) 33.0 (13.2 - 47.4) 0.003
Dmean 24.4 (16.9 - 30.6) 21.3 (12.5 - 27.5) <0.001
PC
D2% 67.3 (63.9 - 73.3) 67.6 (63.5 – 74.0) 0.469
D50% 57.0 (49.1 – 62.0) 53.4 (38.2 - 60.8) 0.021
D98% 36.3 (19.4 - 51.3) 25.1 (11.1 - 43.7) <0.001
SS
D2% 68.0 (61.0 - 77.6) 68.0 (60.8 - 76.6) 0.903
D50% 53.5 (40.5 - 63.8) 47.4 (32.5 - 63.2) 0.003
D98% 34.3 (24.1 - 40.3) 23.3 (12.4 - 31.2) <0.001
Mandible
D2% 53.6 (34.4 - 68.1) 53.6 (35.0 - 66.9) 0.923
The dose distributions of the 3 treatment phases were summed on the pretreatment CT. Reporting is done on manually delineated targets and organs-at-risk.
Statistically significant differences are shown in bold
Abbreviations: s-IMRT step-and-shoot IMRT, IMAT intensity modulated arc therapy, GTVT gross tumor volume of the primary tumor, GTVN GTV of the metastatic
lymph nodes, CTVHR high-risk clinical target volume, PTVHR high-risk planning target volume, CTVEN elective neck CTV, PTVEN elective neck PTV, PRV planning
organ-at-risk volume, SS swallowing structures include the superior, middle and inferior pharyngeal constrictor muscles, upper esophageal sphincter, supraglottic
larynx and upper 2 cm of the cervical esophagus, PC pharyngeal constrictors include the superior, middle and inferior pharyngeal constrictor muscles, Dx% dose
received by x% of the volume, V27Gy % of the volume that receives at least 27 Gy
*Of 10 patients, 6 had metastatic lymph nodes
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Treatment verification
The delivered dose distributions of all IMAT and s-IMRT
treatment plans were verified with the 3D dosimetry system
Delta4 (Scandidos, Uppsala, Sweden). The Delta4 phantom
has 1069 p-type disc-shaped Silicon diodes with a diameter
of 1 mm and axial size 0.05 mm, in a central region (6x6
cm) spaced per 5 mm, outside the central region spaced
per 10 mm. Global gamma indices [14] were deter-
mined in the Delta4 control software for the criteria of
3 % dose difference and 3 mm distance-to-agreement,
the normalization dose being the prescribed dose.
The delivery treatment time was also recorded from
the start of the first beam till the end of the last beam.
Results
Dosimetrical and biological conformity results
Population average dose-volume parameters of targets
and OARs for both strategies are shown in Table 2. Most
of the differences between s-IMRT and IMAT for target
and OAR dose levels were significant (Table 2). Mean
V27Gy of ipsi- and contralateral parotids were improved
by 16.4 % (p = 0.007) and 17.5 % (p = 0.003) in the IMAT
plans, respectively. For the volume of interest that com-
prised the pharyngeal constrictor muscles (PC) and the
one that combined the swallowing structures (SS), both
D50% and D98% levels were significantly improved in the
IMAT plans, while D2% did not show on average any im-
portant differences.
Analysis of each summed dose distribution separately
revealed larger differences for some cases in comparison
with average data. Additional file 1: Figure S1 showed
similar or highly reduced D50% and D98% levels of PC and
SS with up to 54.9 % for IMAT compared to IMRT. D2%
differences of the same structures varied from -2.8 % to
3.6 %. For a cT4a pN2 cM0 oropharynx cancer case the
results were plotted in Fig. 1. IMAT ipsilateral and contra-
lateral parotid mean dose was lowered by 24.9 % and
5.3 %, respectively, while V27 was also improved by 24.9 %
and 6.7 %, respectively. Additional file 2: Figure S2 pro-
vides for the same patient a visual image of how IMAT
isodoses better spare the parotids on every treatment
phase, except for the contralateral parotid on the third
treatment phase. The s-IMRT median dose of the swal-
lowing structures was 22.7 % and 12.3 % higher for the PC
and SS structures.
GTVT quality factors (QF) were significantly better for
the IMAT-plans (p < 0.001 for both DPBN-phases) with
a maximum difference from IMRT factors of -2.1 % in
phase I and II (Table 3). When the QF values of GTVT
and GTVN were considered as one group, a Wilcoxon
test also showed significantly (p < 0.001) lower values for
IMAT.
The integral dose inside the patient was lower for IMAT
in 7 patients with a maximum difference of 14.4 % (Table 4).
For 2 cases, IMAT integral dose was with 2.8 and 3.7 %
higher, while for one case it was similar.
Fig. 1 Radar charts of dose/volume levels comparing s-IMRT and IMAT plans summed on the pretreatment CT for a patient with a cT4a pN2 cM0
oropharynx cancer. The areas are formed by connecting the values belonging to one of the two treatment strategies. Abbreviations: s-IMRT = step-and-
shoot IMRT; IMAT = intensity modulated arc therapy; GTVT = gross tumor volume of the primary tumor; GTVN = GTV of the metastatic lymph nodes;
CTVHR = high risk clinical target volume; PTVHR = high risk planning target volume; CTVEN = elective neck CTV; PTVEN = elective neck PTV; PRV = planning
organ-at-risk volume; SS = swallowing structures – includes superior pharyngeal constrictor, middle pharyngeal constrictor, inferior pharyngeal
constrictor, upper esophageal sphincter, supraglottic larynx and upper 2 cm of the esophagus; PC = pharyngeal constrictors – includes superior
pharyngeal constrictor, middle pharyngeal constrictor and inferior pharyngeal constrictor; Dx% = dose received by x% of the volume; V27Gy = %
of the volume that receives at least 27 Gy
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Delivery results
The data on dosimetric verification of treatment plans,
number of MUs and delivery time are presented in
Table 5. The number of MUs was significantly higher
for IMAT than for s-IMRT plans. All treatments were
delivered on the Elekta linacs while measuring with
the Delta4 system. Mean percentages of the points
with gamma index >1 were 99.7 ± 0.6 % versus 98.7 ±
1.3 % for s-IMRT and IMAT, respectively. On average,
s-IMRT treatment times of phases I, II and III were
6:52, 6:39 and 5:00 min, respectively. IMAT delivery
was significantly shorter: 4:13, 3:44 and 2:56 min,
respectively.
Discussion
In this study we demonstrated the feasibility of a new
18F-FDG-PET-voxel intensity-based IMAT class solution in
our adaptive dose-painting strategy. DPBN imposes heavy
demands to treatment planning and delivery technology in-
cluding high dose gradients and high degree of fluence
modulation. Until now 18F-FDG-PET-voxel intensity-based
s-IMRT has been used in DPBN trials for head-and-neck
cancer [7, 8]. Probably due to limited modulation of s-
IMRT in comparison to IMAT, biologic conformity of
s-IMRT-based DPBN plans was not systematic. Severe
toxicity was also experienced with DPBN-based dose
escalation s-IMRT treatments [7] e.g. mucosal ulcers
and dysphagia. Preliminary data from our clinical trials
suggests that severe toxicity was correlated with dose-
escalation and with smoking and alcohol abuse during
and after treatment. There was no indication that severe
toxicity could be caused by IMRT or the dose painting
concept itself. The search to decrease the toxicity of dose-
escalated treatments by reducing the OAR doses lead to
the development of 18F-FDG-PET-voxel intensity-based
IMAT.
We proposed a method using multiple partial arcs that
would ensure higher flexibility and better conformity in
dose distributions. In IMAT plans, the dose-painting
quality factor evaluating biologic conformity of treat-
ment plans showed significantly better values than for
s-IMRT plans. Although most of the differences in D2%
and D98% for the target structures were significant, they
were not clinically relevant on both individual and aver-
age patient data.
Previous studies showed that in complex-shaped tar-
gets as head-and-neck cancer using a single arc was not
sufficient to reach the quality of IMRT plans [15]. Most
publications report similar or slightly better IMAT
plans (dose coverage and homogeneity in targets) in
comparison with dynamic IMRT or static IMRT at
Table 3 Quality factors (%) of s-IMRT and IMAT dose-painting by
numbers plans of the first two treatment phases
Phase I Phase II
sIMRT IMAT sIMRT IMAT
Patient 1
GTVT 5.1 3.9 4.3 2.8
GTVN1 1.8 1.5 4.6 1.4
GTVN2 2.8 2.0
Patient 2
GTVT 5.0 3.6 4.0 3.2
GTVN1 3.1 2.9 5.3 3.8
Patient 3
GTVT 4.3 2.8 3.6 2.2
Patient 4
GTVT 4.0 4.5 2.6 3.4
Patient 5
GTVT 5.1 3.5 4.5 3.1
Patient 6
GTVT 4.6 2.9 3.2 2.8
Patient 7
GTVT 3.8 4.1 3.4 2.9
Patient 8
GTVT 4.0 2.3 4.9 2.8
GTVN1 2.2 2.5
GTVN2 2.6 2.7
Patient 9
GTVT 3.5 1.9 2.8 1.4
Patient 10
GTVT 5.1 4.1 5.1 4.2
GTVN1 3.9 3.4 5.1 2.4
Dose painting inside GTVN was done only for the cases where the PET signal
was high enough
Abbreviations: s-IMRT step-and-shoot IMRT, IMAT intensity modulated arc
therapy, GTVT gross tumor volume of the primary tumor, GTVNx metastatic
18F-FDG-PET-positive lymph node
Table 4 Integral Dose (J) calculated on the pretreatment CT
scans inside the patient volume
Patient No. s-IMRT IMAT Δ%
1 243.1 238.4 -1.9
2 274.4 274.3 0.0
3 115.3 109.1 -5.4
4 125.1 123.6 -1.2
5 135.3 129.1 -4.6
6 120.5 124.9 3.7
7 130.2 128.9 -1.0
8 150.1 128.6 -14.4
9 104.4 101.6 -2.7
10 160.1 164.6 2.8
Abbreviations: s-IMRT step-and-shoot IMRT, IMAT intensity modulated
arc therapy
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conventional dose prescription, when double or triple
full arcs were used [4, 5, 15–20].
IMAT has the potential to decrease doses to OARs
[4, 5, 15–21] that becomes crucially important in dose-
escalation treatment protocols. In s-IMRT plans we
usually sacrifice the ipsilateral parotid, if the tumor or
metastatic lymph node is at the level of the gland. A
previous study [22] showed that adapting treatment to
anatomic changes in the glands could lower doses even
in the ipsilateral parotid. The current study results
demonstrate that IMAT could further spare both pa-
rotids by significantly reducing Dmean (by 14.0 % and
12.7 % for the ipsilateral and contralateral parotid, re-
spectively) and V27Gy (by 16.4 % and 17.5 % for the ipsi-
lateral and contralateral parotid, respectively) as compared
to s-IMRT, both treatments being adaptive. Vanetti et al.
[5] obtained a significant reduction of parotid Dmean using
two full arcs against dynamic IMRT by 14.0 % and 13.5 %
for the ipsilateral and contralateral parotid, respectively.
Other studies employing double or triple full arcs
Table 5 Delivery analysis of each treatment phase: number of monitor units (MUs), treatment time (minutes:seconds) - registered
from the beginning of the first beam till the end of the last beam - and the percentage of the measurement points with γ < 1 -
which compares Delta4 measurements and Pinnacle dose calculations
Patient Phase Number of MUs Treatment time % of points with γ < 1
s-IMRT IMAT s-IMRT IMAT s-IMRT IMAT
1 I 609 792 8:13 5:15 100.0 98.4
II 515 671 8:03 3:49 100.0 96.8
III 599 777 6:05 3:41 100.0 98.5
2 I 646 742 9:00 4:27 100.0 98.6
II 646 803 8:13 3:30 100.0 97.5
III 448 616 5:50 3:35 99.4 98.9
3 I 415 725 6:11 3:56 100.0 97.8
II 436 734 6:30 3:15 100.0 96.1
III 310 877 5:00 4:12 97.3 94.3
4 I 384 737 5:50 3:48 100.0 98.8
II 409 671 5:55 4:12 99.6 98.6
III 283 575 5:02 3:05 99.4 98.7
5 I 438 719 5:50 3:47 100.0 99.7
II 417 751 6:12 3:12 100.0 97.4
III 235 226 4:24 1:27 100.0 100.0
6 I 520 809 6:13 3:14 100.0 99.8
II 466 748 5:55 3:23 100.0 98.4
III 263 424 4:22 2:35 100.0 100.0
7 I 538 695 6:10 4:20 100.0 99.9
II 591 738 6:30 3:49 100.0 100.0
III 263 664 5:00 3:05 99.5 99.4
8 I 689 672 9:00 3:36 99.7 99.0
II 437 595 6:32 4:06 100.0 100.0
III 368 740 4:15 3:54 99.8 98.2
9 I 450 708 5:26 4:51 100.0 99.2
II 464 674 5:41 3:34 99.9 99.7
III 315 322 4:46 1:56 98.4 100.0
10 I 545 746 6:47 5:03 100.0 100.0
II 562 759 7:07 4:37 99.8 98.6
III 336 270 5:25 1:52 99.4 99.6
p-value < .0001 < .0001 < .0001
Two-sided Wilcoxon matched-pair signed rank test p-values are given on the last row
Abbreviations: s-IMRT step-and-shoot IMRT, IMAT intensity modulated arc therapy
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demonstrated similar contributions to parotid Dmean by
IMAT and IMRT [15, 16, 19]. With IMAT we could also
better spare other OARs - the spinal cord, brainstem,
pharyngeal constrictor muscles and swallowing structures -
except the mandible (Table 2) a finding in agreement with
Vanetti et al. [5]. Reduction in doses to OARs was even
more evident in individual patients (Additional file 1:
Figure S1 and Additional file 2: Figure S2).
Most retrospective [4, 5, 15–20] and prospective [21]
IMAT-IMRT comparisons report a lower number of
MUs for the arc therapy plans, although some report
higher MUs [16, 26]. Our IMAT plans had on average
higher MUs than IMRT plans, which might be of less
concern due to the following reasons. The integral dose
inside the patient (Table 4) showed that for IMAT plans
the theoretical risk of developing secondary malignancies
was less or similar to the s-IMRT plans. By delivering
more dose to the surrounding tissues, based on the linear-
non-threshold-model, an increase in secondary neoplasm
can be expected [23]. Furthermore, the latest commer-
cially available MLC devices are characterized with very
low leakage and hence the overall patient exposure to low
doses is highly reduced [24–26]. The linac head and MLC
leakage is even further reduced in the case of flattening fil-
ter free linacs [27].
Our IMAT plan measurements showed that a discrete
dose calculation per 8° was not always a good approxi-
mation of the arc delivery (data not shown). There are
two reasons likely to cause the lower gamma index per-
centages for the IMAT QA: one is the discretization (to
a limited number of gantry angles) used in the dose
computation, the second is the higher number of Monitor
Units (MU) for the IMAT plans together with smaller
fields. By CP refinement and further optimization, gamma
percentages higher than 94.3 % could be achieved. The
single arc plans of Bertelsen et al. [18] gave slightly better
average percentages for gamma < 1 (99.6 ± 0.5 %) as com-
pared to the multiple partial arc plans of the present study
(98.7 ± 1.3 %). Korreman et al. [28] got 89.6 %, 88.5 % and
92.2 % for double arc plans corresponding to 3, 7 and
11 dose-painting-by-contours prescribed levels for one
individual case. The reliability of Delta4 phantom mea-
surements for IMRT and IMAT was studied by Bedford et
al. [29]. We would like to point out that the spacing of 0.5
and 1 cm between the Delta4 array detectors was rather
limited for the high dose gradients of DPBN plans.
Rotational treatment shortens delivery time thus im-
proving comfort for the patient and reducing risk of pa-
tient movement during treatment, which cannot be
neglected [30]. By eliminating parts of the arcs with very
low contribution and linking them in one arc, IMAT
treatment delivery time became in the range 1.3 to
5.2 min, which despite dose escalation, was comparable
or even faster than published data on single, double or
triple full arc plans using conventional prescription
doses to targets [5, 15–20].
Conclusions
IMAT implementation in an adaptive dose-escalation
biological image-guided treatment strategy lead to sig-
nificantly better biological quality factors in comparison
to s-IMRT. The method was superior in reducing dose
to OARs, biologic conformity and treatment efficacy.
IMAT treatment delivery was significantly faster than s-
IMRT and the multiple partial arc class solution made it
one of the fastest reported in literature. Hence more pa-
tients can be treated per day with more comfort and less
intra-fraction movements.
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Additional files
Additional file 1: Figure S1. Individual patient IMAT and s-IMRT dose
levels (D2%, D50%, D98%) for the volume of interest that comprises the
pharyngeal constrictor muscles (PC) and the one that combines the
swallowing structures (SS). Each graph presents the 10 individual patient
values of one volume of interest dose level for the total summed dose
distribution on the pretreatment CT. X and y axes show the s-IMRT and
IMAT dose values (Gy). The marker position above or below the identity line
(dotted) correspond to a higher or lower IMAT dose level value in comparison
with s-IMRT, respectively. Abbreviations: s-IMRT = step-and-shoot IMRT;
IMAT = intensity modulated arc therapy; PC = pharyngeal constrictor –
includes superior pharyngeal constrictor, middle pharyngeal constrictor
and inferior pharyngeal constrictor; SS = swallowing structures – includes
superior pharyngeal constrictor, middle pharyngeal constrictor, inferior
pharyngeal constrictor, upper esophageal sphincter, supraglottic larynx and
upper 2 cm of the esophagus; Dx% = dose received by x% of the volume.
(TIF 792 kb)
Additional file 2: Figure S2. s-IMRT (first row) and IMAT (second row)
dose distributions for the 3 treatment phases of a patient with a cT4a
pN2 cM0 oropharynx cancer. Isodoses are displayed on the CT transverse
images. For phases I and II the contrast-enhanced 18F-FDG-PET image set
is superposed on the CT. The regions of interest contours are drawn as
follows: GTVT and GTVN in red, CTVHR in purple, PTVHR in blue and the
parotids in green (colorwash). Abbreviations: s-IMRT = step-and-shoot
IMRT; IMAT = intensity modulated arc therapy; GTVT = gross tumor volume
of the primary tumor; GTVN = GTV of the metastatic lymph nodes;
CTVHR = high risk clinical target volume; PTVHR = high risk planning
target volume. (TIF 1747 kb)
Abbreviations
18F-FDG-PET: 2-deoxy-2-(18F)fluoro-D-glucose positron emitting tomography;
ABAS: Elekta’s atlas-based autosegmentation; ABST: anatomy-based
segmentation tool; BBST: biology-based segmentation tool; CPs: control
points; CT: computed tomography; CTVHR: high risk clinical target volume;
CTVEN: elective neck clinical target volume; Dmean: mean dose; DPBN: dose-
painting-by-numbers; Dx%: dose received by x % of the volume; GTVNx: gross
tumor volume of pathological lymph node(s); GTVT: gross tumor volume of
the primary tumor; Gy: gray; IMAT: intensity-modulated arc therapy;
MU: monitor unit; MV: megavolt; OAR: organ-at-risk; PC: pharyngeal
constrictor; PRV: planning risk volume; PTVEN: elective neck planning target
volume; PTVHR: high risk planning target volume; QF: quality factor;
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ROI: region of interest; s-IMRT: step-and-shoot intensity modulated
radiotherapy; SPSS: IBM statistical package for the social sciences;
SS: swallowing structures; SUVMAX: maximal standardised uptake value;
VxGy: volume receiving x Gy.
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